Intelligence Feed event · Policy · 2026-09-03

    NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC

    Question

    NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC

    Direct answer

    Revolution Medicines (RVMD) announced that the New England Journal of Medicine has published complete Phase 1/2 data for RASONQUE (daraxonrasib) targeting previously treated RAS mutant non-small cell lung cancer (NSCLC). The published dataset demonstrated a 42% objective response rate alongside a median overall survival of 16.0 months. High-impact academic publication validates the drug's mechanistic profile and solidifies clinical benchmarks ahead of registrational trial readouts.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/nejm-publishes-revolution-medicines-phase-1-2-data-showing-42-orr-in-nsclc-28993d

    POLICY
    NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC
    Revolution Medicines (RVMD) announced that the New England Journal of Medicine has published complete Phase 1/2 data for RASONQUE (daraxonrasib) targeting previously treated RAS mutant non-small cell lung cancer (NSCLC). The published dataset demonstrated a 42% objective response rate alongside a median overall survival of 16.0 months. High-impact academic publication validates the drug's mechanistic profile and solidifies clinical benchmarks ahead of registrational trial readouts.
    RVMD
    Impact
    74
    SEP 3
    SIG
    92%
    RVMD
    NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC
    Revolution Medicines (RVMD) announced that the New England Journal of Medicine has published complete Phase 1/2 data for RASONQUE (daraxonrasib) targeting previously treated RAS mutant non-small cell lung cancer (NSCLC). The published dataset demonstrated a 42% objective response rate alongside a median overall survival of 16.0 months. High-impact academic publication validates the drug's mechanistic profile and solidifies clinical benchmarks ahead of registrational trial readouts.
    → Peer-reviewed publication of 42% ORR and 16.0-month median OS de-risks clinical development milestones and raises commercial pipeline valuation for RVMD.
    Impact
    Revolution Medicines (RVMD) announced that the New England Journal of Medicine has published complete Phase 1/2 data for RASONQUE (daraxonrasib) targeting previously treated RAS mutant non-small cell lung cancer (NSCLC). The published dataset demonstrated a 42% objective response rate alongside a median overall survival of 16.0 months. High-impact academic publication validates the drug's mechanistic profile and solidifies clinical benchmarks ahead of registrational trial readouts.
    Affected
    RVMD
    Transmission
    Peer-reviewed publication of 42% ORR and 16.0-month median OS de-risks clinical development milestones and raises commercial pipeline valuation for RVMD.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDclinical pipeline de-risking following peer-reviewed NEJM publicationUp1-4wNEJM published Phase 1/2 data showing 42% ORR and 16.0 months median OS for RASONQUE.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month